Answers are grounded in this paper and cite their sources.
This study evaluated dietary octapeptin as an alternative to enramycin for alleviating Clostridium perfringens-associated damage in broilers. A total of 240 one-day-old Lingnan Yellow broilers were assigned to four groups with six replicates of 10 birds: an unchallenged control, a challenged control, and challenged groups receiving enramycin (10 mg/kg) or octapeptin (40 mg/kg). The trial lasted 21 days. Clostridium perfringens challenge successfully induced necrotic enteritis: compared with the unchallenged control, the challenged control showed lower final body weight, and higher intestinal lesion scores. Compared with the challenged control, both additives increased final body weight and reduced serum alanine aminotransferase, lactate dehydrogenase, interferon-γ, and interleukin-6 (p < 0.05). Octapeptin additionally reduced serum alkaline phosphatase and increased high-density lipoprotein cholesterol (p < 0.05). Both additives reduced jejunal NLRP3, CASP1, MyD88, and NF-κB expression and ileal CASP1 expression, while octapeptin also reduced jejunal TLR2 and ileal TLR2 and TGF-β1 expression (p < 0.05). Moreover, octapeptin alleviated jejunal villus atrophy, as indicated by greater villus height and a higher villus height-to-crypt depth ratio, and restored jejunal occludin expression (p < 0.05), indicating preserved mucosal architecture and barrier integrity. Serum interleukin-1β remained elevated despite supplementation. These findings support octapeptin as a potential alternative to enramycin for alleviating growth depression and intestinal injury, with benefits associated with improved serum biochemical indicators and reduced inflammatory responses.
No takes yet. Share an insight, caveat, or question.
Diao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: